Photocure, the world leader in photodynamic technology, is a Norwegian based specialty pharmaceutical company. They develop and commercialize highly selective and effective solutions in several disease areas such as bladder cancer, colorectal cancer, HPV and precancerous lesions of the cervix, acne and other dermatologic conditions. These products are based on the proprietary Photocure Technology™ platform.
Photocure is headquartered in Oslo, Norway, listed on the Oslo Stock Exchange, and operates in Norway, Sweden, Denmark, Finland and the United States. They have two marketed products that they commercialize directly in the US and the Nordic region:
– Hexvix®/Cysview®, for detection of bladder cancer (the brand name is Cysview in the US and Hexvix in the rest of the world)
– Allumera®, for skin revitalization (the product is available only in the US)
They have several products in the pipeline, based on their proprietary Photodynamic Technology platform, and are continuously exploring new therapeutic areas. Products in the pipeline include:
– Cevira® – for the treatment of HPV and precancerous lesions of the cervix
– Visonac® – for the treatment of moderate to severe acne
– Lumacan® – for the detection of colorectal cancer
Photocure pursue a flexible approach to development and commercialization, leveraging in-house capabilities with those of selected strategic partners. In 2011 they entered into a strategic collaboration with Ipsen Pharma for the commercialization of Hexvix worldwide (excluding the US and Nordic region). In 2010 they entered into a strategic global agreement with Salix Pharmaceuticals for the development and commercialization of Lumacan.
Photodynamic technology combines a substance (photosensitizer) with exposure to light, providing effective solutions for diagnosis and treatment. Depending on the photosensitizer and the light source, photodynamic technology can be used in a variety of applications. The great advantage is that the reaction only takes place in the affected area/cells exposed to light.
Photocure’s technology provides important qualities that further enhance the properties of photodynamic therapeutic, diagnostic and cosmetic applications. Photocure Technology™ is uniquely selective, targeting affected areas without impact to non-affected areas. This allows for non-invasive procedures that improve quality of life.
Detection of bladder cancer: The first photo shows a bladder with cancer using standard white light cystoscopy. The second shows the same bladder using Hexvix cystoscopy. The cancer cells light up red in the blue light. Pictures courtesy of Dirk Zaak, Professor, Dept. of Urology, University of Munich, Germany.
Allumera®, Photocure® and Cysview(®)/Hexvix® are registered trademarks of Photocure ASA.